The calcifediol pharmaceutical-grade active pharmaceutical ingredient described in this monograph is supplied as a white to off-white crystalline powder under internal article codes CF-25-OH-PG for oral solid dosage and CF-25-OH-IG for injectable dosage. The product is released in two specification branches: an oral solid grade intended for tablet compression, capsule filling, and granule sachets, and an injectable grade intended for non-aqueous or micellar parenteral products. Chemical identity is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3β,25-diol, CAS 19356-17-3, molecular formula C₂₇H₄₄O₂, and molar mass 400.64 g/mol. The compound is a lipophilic secosteroid with an n-octanol/water partition coefficient log P of approximately 5.7, aqueous solubility below 1 mg/L at 25°C, and melt onset in differential scanning calorimetry of approximately 78–88°C depending on polymorphic form and hydration state. The API is packed in double low-density polyethylene bags inside sealed aluminium foil pouches under a nitrogen atmosphere and is stored at ≤ 8°C.

What distinguishes calcifediol from cholecalciferol, alfacalcidol, and calcitriol in pharmaceutical processing?

Calcifediol is the 25-hydroxylated metabolite of cholecalciferol; the added C-25 hydroxyl group removes the need for hepatic CYP2R1-dependent 25-hydroxylation and provides a circulating half-life in the range of 15–21 days, compared with 4–6 hours for calcitriol. Plasma transport is dominated by vitamin D-binding protein; calcifediol has a higher binding affinity than calcitriol, which reduces free-hormone fluctuations during once-daily or extended-interval dosing. Unlike calcitriol, calcifediol requires target-tissue 1α-hydroxylation by CYP27B1 for full vitamin D receptor activation; therefore, its activity is partially dependent on residual renal enzyme function. Unlike alfacalcidol, which is already 1α-hydroxylated and acts independently of renal CYP27B1, calcifediol is not the preferred active form when renal 1α-hydroxylase activity is negligible. Compared with vitamin D2 ergocalciferol, calcifediol shows higher human vitamin D-binding protein affinity and a more sustained plasma concentration profile across oral dose intervals. These pharmacological differences translate into manufacturing differences: calcifediol is a crystalline solid, whereas cholecalciferol is an oily liquid at room temperature and must be adsorbed onto silica or starch for solid dosage forms.

The product is used in tablets and capsules containing 20–50 µg per unit and in granules intended for sachets at 30–266 µg per unit. Injectable use is limited to non-aqueous or micellar presentations; published dosing data for injectable calcifediol are sparse compared with oral formulations. Pharmacopoeial alignment for the API includes an HPLC purity platform with a reversed-phase C18 column, an acetonitrile/water mobile phase, and ultraviolet detection at 265 nm. The system suitability solution resolves calcifediol from pre-calcifediol and trans-calcifediol at a resolution factor not less than 2.0; the tailing factor for calcifediol is not more than 2.0. Assay calculations are performed on the anhydrous, solvent-free basis using an external calcifediol reference standard.

Chromatographic purity, isomer control, and particulate specifications for oral and injectable grades

The two branches share a common purity platform but differ in residual solvent burden, water content, particulate dimension, and microbiological controls. The table below presents pharmacopoeial and ICH-based release parameters.

Direct compression of the oral solid grade at 20–50 µg per tablet is constrained by blend uniformity rather than compactability. Because the API is present at less than 0.1% by weight in a typical 200 mg tablet, three-stage geometric dilution with pre-sieved lactose monohydrate is used before tumble blending. Blend assay relative standard deviation after blending at 25 rpm for 15 min is targeted at ≤ 2.0%, and tablet content uniformity is assessed per USP <905> with acceptance value L1 ≤ 15.0. Compression on a rotary tablet press with 8 mm round biconvex tooling at 5–10 kN produces cores with tensile strength of 1.5–2.5 MPa; ejection forces above 800 N are treated as a processing warning because excessive lubricant or residual moisture can induce die-wall sticking. Batch-to-batch particle size variation is controlled by laser diffraction with D10 ≥ 5 µm, D50 15–25 µm, and D90 ≤ 90 µm for oral solid lots. Unseeded cooling crystallizations can produce broad melting endotherms and unacceptable tablet sticking; therefore, seeded cooling and post-milling particle conditioning are specified.

For capsule products, low-dose dosator or tamping-pin filling machines are used with fill weights from 80 mg to 250 mg. The API is either pre-blended with mannitol and croscarmellose sodium or dissolved in medium-chain triglycerides with 0.05% butylated hydroxytoluene for lipid-filled hard-shell capsules. Gelatin capsule shells filled with lipid vehicles require band-sealing to prevent leakage at 40°C/75% RH; hypromellose shells can be sealed with a polymer film. Oral absorption of calcifediol is influenced by the presence of dietary fat and bile salts. Lipid-filled hard-shell capsules present the API in a pre-solubilized state, which can reduce fasted-state variability relative to dry blends; however, lipid-filled capsules show a higher incidence of shell leakage at elevated storage temperature. Dry blends in tablets are more stable physically but may require dissolution surfactants such as sodium lauryl sulfate at 0.1–0.5% to achieve acceptable in vitro release.

Granule platforms for sachets use ethanol or isopropanol as the granulation solvent, povidone K30 as binder, and mannitol or lactose as diluent. Fluid-bed drying is limited to 30–40°C inlet air; exposure above 45°C for more than 60 min increases pre-calcifediol formation. The dried granules are milled through a 0.8 mm conical screen and filled under nitrogen at a residual moisture of ≤ 0.5% water. Granule losses from dusting are controlled by adding binder solution at 5–8% of dry powder mass; when binder level exceeds 10%, sachet dissolution slows and tablet-like granules become difficult to disperse.

Injectable-grade calcifediol is formulated in non-aqueous vehicles or aqueous micellar systems. The API is dissolved in ethanol/propylene glycol or a parenteral-grade oil before aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane. Terminal steam sterilization is incompatible with the triene pharmacophore because thermal degradation accelerates steeply above 40°C. Finished vials are nitrogen-purged, closed with bromobutyl rubber stoppers, and stored at 2–8°C shielded from light. Injectable formulations that use ethanol/propylene glycol can cause pain on injection; a common modification is dilution with a parenteral-grade oil such as refined sesame oil or a micellar system containing polysorbate 80 and sodium deoxycholate at concentrations not exceeding the approved daily exposure limits. In micellar systems, the drug load is typically below 0.1% w/v, and the formulation is filtered through a 0.22 µm membrane under nitrogen pressure.

When calcifediol is selected for pediatric granule sachets rather than oil-based injection, processing benchmarks shift toward low-dose uniformity and water activity control

The sachet granule format requires water activity below 0.3 at 25°C to prevent microbial growth and reduce moisture sorption during filling. Because the target dose can be 20 µg or lower in pediatric presentations, the API is added as a dilute pre-blend at 1:20 with spray-dried lactose; final blend uniformity is verified by stratified sampling at 3, 6, and 12 min during blending. Sachet fill weights are 1.0–2.0 g on a vertical form-fill-seal machine with nitrogen purging. The packaging laminate is paper/aluminium/polyethylene with an oxygen transmission rate of ≤ 0.1 cm³/m²/24 h at 23°C/0% RH. In injectable processing, the critical parameter shifts from blend uniformity to filterability and bioburden control; a final filtration train with 0.45 µm followed by 0.22 µm membranes is used, and the maximum filtration pressure is maintained below 1.0 bar to avoid membrane deformation. The oral solid grade is not suitable for parenteral administration because it is not sterilized and has a higher particulate burden; conversely, the injectable grade imposes cost and particle-size overhead that is unnecessary for tablet or capsule processing.

Thermal and photochemical stability boundaries govern terminal sterilization choices

Calcifediol is sensitive to light in the UV-blue region; photochemical conversion to pre-calcifediol occurs in solution when exposed to wavelengths below 450 nm. Manufacturing areas for injection are therefore equipped with low-actinic amber lighting, and oral tablet cores are coated with polyvinyl alcohol–polyethylene glycol copolymer films containing titanium dioxide or iron oxide. Thermal degradation studies in solution show an Arrhenius-like increase in trans-calcifediol above 40°C; drying, milling, and sterilization operations are therefore conducted under continuous temperature monitoring. If a product requires a sterility assurance level of 10⁻⁶, aseptic processing with media-fill validation per EU GMP Annex 1 is used instead of terminal moist-heat sterilization at 121°C.

Solid-state compatibility data show that acidic excipients such as citric acid monohydrate increase isomerization in wet granulation; therefore, neutral or slightly alkaline diluents are selected for calcifediol tablets and granules. The API is not combined with cyclodextrins that contain reducing sugar impurities in aqueous injectable formulations, because trace metal sites and reducing moieties can oxidize the conjugated triene system. Calcifediol oral solid intermediates are stored at ≤ 8°C for long-term stability, whereas cholecalciferol oil can be stored at room temperature; this temperature difference arises from the greater propensity of calcifediol to isomerize or lose the C-25 hydroxyl when exposed to moisture and heat. The product is not suitable for use in aqueous granulation unless ethanol is used as the granulation solvent, because water acts as a plasticizer and can accelerate degradation of the conjugated triene system at elevated temperature. Production-scale data comparing all four dosage platforms for calcifediol are limited; the processing limits above are derived from manufacturer specifications, ICH stability guidance, and standard parenteral manufacturing practice.